Evidence Based Medicine presented by InpharmD™

A single-blind, multicenter, randomized, controlled trial conducted to evaluate the efficacy of financial incentives dependent on continuous smoking abstinence on smoking cessation and birth outcomes among pregnant smokers.

An open-label, randomized, parallel-group, adaptive design with blinded outcome adjudication trial conducted to compare the efficacy and safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty.

The first in-human, phase 1, randomized, double-blind, placebo-controlled study conducted to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of molnupiravir in healthy subjects.

A double-blind, randomized, placebo-controlled trial conducted to assess the role of chlorthalidone for hypertension in advanced chronic kidney disease.

An investigator-initiated, multi-center, randomized, double-blind, superiority, placebo-controlled conducted to determine whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves return of spontaneous circulation.

A randomized, adaptive, platform trial conducted to assess the efficacy of fluvoxamine versus placebo in preventing hospitalization (defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19).

A randomized, double-blind, placebo-controlled, phase 3 study, conducted to evaluate the efficacy and safety MDMA-assisted therapy for PTSD compared with placebo with therapy?

A randomized, double-blind, parallel-group, placebo-controlled, event-driven trial conducted to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes in patients with heart failure and a preserved ejection fraction.

This week, InpharmD looks at two case reports discussing presentations of patients who developed Functional Neurological Disorder (FND) after receiving COVID-19 vaccination.